GRI · GRI Bio, Inc. · Investor Relations
$1.47
+0.01 (+0.68%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.19M
Shares
2.19M
Volume · Oct 21
58.96K
Avg daily vol (3M)
325.56K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-30 | GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit | Event |
| 2026-09-09 | GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | Event |
| 2026-09-05 | GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | Event |
| 2026-03-02 | H.C. Wainwright KOL Event | Event |
| 2026-02-11 | Corporate Connect Webinar Series hosted by Webull Financial | Event |
| 2025-05-18 | 2025 ATS International Conference | Conference |
Source: https://gribio.com/investors/